TN2009000045A1 - Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level - Google Patents

Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level

Info

Publication number: TN2009000045A1
Authority: TN; Tunisia
Prior art keywords: treatment; heterocyclic compounds; diseases related; compounds suitable; lipid level
Prior art date: 2006-08-15

Application number

TN2009000045A

Other languages

English (en)

Inventor

Jianmin Fu

Rajender Kamboj

Shifeng Liu

Natalia Pokrovskaia

Vandna Raina

Shaoyi Sun

Zaihui Zhang

Natalie Dales

Julia Fonarev

Vishnumurthy Kodumuru

Original Assignee

Novartis Ag

Xenon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-15

Filing date

2009-02-13

Publication date

2010-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39864516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000045(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-02-13 Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag

2010-08-19 Publication of TN2009000045A1 publication Critical patent/TN2009000045A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Virology (AREA)
Dermatology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Oncology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Nutrition Science (AREA)
Tropical Medicine & Parasitology (AREA)

TN2009000045A 2006-08-15 2009-02-13 Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level TN2009000045A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82245906P	2006-08-15	2006-08-15
PCT/US2007/075802 WO2008127349A2 (fr)	2006-08-15	2007-08-13	Composés organiques

Publications (1)

Publication Number	Publication Date
TN2009000045A1 true TN2009000045A1 (en)	2010-08-19

Family

ID=39864516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2009000045A TN2009000045A1 (en)	2006-08-15	2009-02-13	Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level

Country Status (27)

Country	Link
US (2)	US8063084B2 (fr)
EP (1)	EP2054408B1 (fr)
JP (1)	JP4972690B2 (fr)
KR (4)	KR20140019873A (fr)
CN (1)	CN101535303B (fr)
AR (1)	AR062360A1 (fr)
AU (1)	AU2007351498B2 (fr)
BR (1)	BRPI0716407A2 (fr)
CA (1)	CA2660201C (fr)
CL (1)	CL2007002348A1 (fr)
CO (1)	CO6241156A2 (fr)
CR (1)	CR10566A (fr)
ES (1)	ES2597453T3 (fr)
GT (1)	GT200900027A (fr)
IL (1)	IL196562A0 (fr)
MA (1)	MA30655B1 (fr)
MX (1)	MX2009001634A (fr)
MY (1)	MY153263A (fr)
NO (1)	NO20091083L (fr)
NZ (2)	NZ574222A (fr)
PE (3)	PE20110371A1 (fr)
RU (1)	RU2009109147A (fr)
TN (1)	TN2009000045A1 (fr)
TW (1)	TWI404718B (fr)
UA (1)	UA96766C2 (fr)
WO (1)	WO2008127349A2 (fr)
ZA (1)	ZA200900263B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20140019873A (ko) *	2006-08-15	2014-02-17	노파르티스 아게	증가된 지질 수준과 관련된 질환의 치료에 적합한 헤테로시클릭 화합물
AU2007336238A1 (en) *	2006-12-20	2008-06-26	Novartis Ag	2-substituted 5-membered heterocycles as SCD inhibitors
EA017252B1 (ru)	2007-08-28	2012-11-30	Айрм Ллк	Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
JP5507474B2 (ja)	2008-02-20	2014-05-28	ノバルティスアーゲー	ステアロイル−ＣｏＡデサチュラーゼのヘテロ環式阻害剤
AU2013200845B2 (en) *	2008-02-20	2015-01-29	Xenon Pharmaceuticals Inc.	Heterocyclic inhibitors of stearoyl-CoA desaturase
US8445505B2 (en)	2008-06-25	2013-05-21	Irm Llc	Pyrimidine derivatives as kinase inhibitors
UY31929A (es)	2008-06-25	2010-01-05	Irm Llc	Compuestos y composiciones como inhibidores de cinasa
JP5597210B2 (ja)	2009-02-17	2014-10-01	メルクカナダインコーポレイテッド	ステアロイル−補酵素ａデルタ−９デサチュラーゼの阻害剤として有用な新規スピロ化合物
WO2011011872A1 (fr)	2009-07-28	2011-02-03	Merck Frosst Canada Ltd.	Nouveaux composés spiro utiles en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
CN102574841A (zh) *	2009-10-01	2012-07-11	诺瓦提斯公司	调节硬脂酰-coa去饱和酶的吡唑衍生物
WO2013009678A2 (fr) *	2011-07-08	2013-01-17	Indiana University Research And Technology Corporation	Compositions et méthodes de traitement d'infection par un norovirus
RU2014119426A (ru)	2011-10-15	2015-11-20	Дженентек, Инк.	Способы применения антагонистов scd1
US9505728B2 (en)	2012-03-09	2016-11-29	Inception 2, Inc.	Triazolone compounds and uses thereof
EP2858501A4 (fr) *	2012-05-22	2015-12-09	Merck Sharp & Dohme	Inhibiteurs de kinase trk-a, compositions et méthodes correspondantes
WO2013175474A2 (fr)	2012-05-22	2013-11-28	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Inhibiteurs sélectifs de cellules indifférenciées
DK2935228T3 (en)	2012-12-20	2017-10-30	Inception 2 Inc	TRIAZOLONE COMPOUNDS AND APPLICATIONS THEREOF
KR20160048988A (ko)	2013-09-06	2016-05-04	인셉션 2 인코퍼레이티드	트라이아졸론 화합물 및 이의 용도
JP6389531B2 (ja) *	2014-04-28	2018-09-12	ジアンスカニョンファーマシューティカルカンパニーリミテッド	抗エンテロウイルス７１チアジアゾリジン誘導体
US10208081B2 (en)	2014-11-26	2019-02-19	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
AU2016242861B2 (en)	2015-03-31	2020-08-20	Enanta Phamraceuticals, Inc.	Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2017189652A1 (fr)	2016-04-26	2017-11-02	Enanta Pharmaceuticals, Inc.	Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs procédés d'utilisation
US10080743B2 (en)	2016-04-26	2018-09-25	Enanta Pharmaceuticals, Inc.	Isoxazole derivatives as FXR agonists and methods of use thereof
US10080742B2 (en)	2016-04-26	2018-09-25	Enanta Pharmaceuticals, Inc.	Isoxazole derivatives as FXR agonists and methods of use thereof
US10138228B2 (en)	2016-05-18	2018-11-27	Enanta Pharmaceuticals, Inc.	Isoxazole derivatives as FXR agonists and methods of use therof
US10144729B2 (en)	2016-05-18	2018-12-04	Enanta Pharmaceuticals, Inc.	Isoxazole analogs as FXR agonists and methods of use thereof
WO2017201155A1 (fr)	2016-05-18	2017-11-23	Enanta Pharmaceuticals, Inc.	Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs méthodes d'utilisation
MX2019003790A (es)	2016-10-04	2019-09-26	Enanta Pharm Inc	Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
WO2018081167A1 (fr)	2016-10-24	2018-05-03	Yumanity Therapeutics	Composés et utilisations de ces derniers
US10597391B2 (en)	2016-10-26	2020-03-24	Enanta Pharmaceuticals, Inc.	Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
IL304017A (en)	2017-01-06	2023-08-01	Yumanity Therapeutics Inc	Methods for treating neurological disorders
EP3700934A4 (fr)	2017-10-24	2021-10-27	Yumanity Therapeutics, Inc.	Composés et utilisations de ces composés
WO2019118571A1 (fr)	2017-12-12	2019-06-20	Enanta Pharmaceuticals, Inc.	Analogues de l'isoxazole utilisés en tant qu'agonistes de fxr et leurs procédés d'utilisation
US10829486B2 (en)	2018-02-14	2020-11-10	Enanta Pharmacueticals, Inc.	Isoxazole derivatives as FXR agonists and methods of use thereof
SG11202009280RA (en)	2018-03-23	2020-10-29	Yumanity Therapeutics Inc	Compounds and uses thereof
SG11202108079RA (en)	2019-01-24	2021-08-30	Yumanity Therapeutics Inc	Compounds and uses thereof
US11555032B2 (en)	2019-05-13	2023-01-17	Enanta Pharmaceuticals, Inc.	Isoxazole derivatives as FXR agonists and methods of use thereof
CN111961034A (zh) *	2019-05-20	2020-11-20	浙江同源康医药股份有限公司	用作ret激酶抑制剂的化合物及其应用
EA202192047A1 (ru)	2019-11-13	2021-12-08	Юманити Терапьютикс, Инк.	Соединения и их применение
GB202012969D0 (en) *	2020-08-19	2020-09-30	Univ Of Oxford	Inhibitor compounds
CN115286616A (zh) *	2022-07-27	2022-11-04	北京师范大学	结合sigma-2受体的四氢异喹啉和异吲哚啉类化合物、其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL293361A (fr) *	1962-05-30
CH455806A (de) *	1963-08-30	1968-05-15	Ciba Geigy	Verfahren zur Herstellung neuer Imidazole
CH463517A (de) *	1964-04-24	1968-10-15	Ciba Geigy	Verfahren zur Herstellung neuer Diazacycloalkanverbindungen
US4058617A (en) *	1972-10-04	1977-11-15	Ciba-Geigy Corporation	Imidazoles and pharmaceutical composition
CH590266A5 (fr) *	1972-10-04	1977-07-29	Ciba Geigy Ag
IL44282A (en)	1974-02-25	1979-01-31	Ciba Geigy Ag	1-(1-alkyl-4(5)nitro-imidazol-2-yl)-2-oxo-tetrahydroimidazole derivatives, their manufacture and pharmaceutical compositions containing them
NZ184081A (en) *	1976-06-01	1980-10-08	Velsicol Chemical Corp	1-thiazol-2-yl-1 3-imidazolidn-2-ones
US4086240A (en) *	1976-06-01	1978-04-25	Velsicol Chemical Corporation	1-Thiazolyl-5-phenoxy and phenylthioalkanoyloxyimidazolidinones
US4116969A (en)	1976-06-01	1978-09-26	Velsicol Chemical Company	1-thiazolyl-5-hydroxyimidazolidinones
FI90869C (fi) *	1986-11-14	1994-04-11	Tanabe Seiyaku Co	Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
US5164403A (en) *	1991-04-05	1992-11-17	G. D. Searle & Co.	N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
AU5735096A (en) *	1995-05-17	1996-11-29	E.I. Du Pont De Nemours And Company	Fungicidal cyclic amides
DE19732928C2 (de)	1997-07-31	2000-05-18	Gruenenthal Gmbh	Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
ATE257703T1 (de)	1997-10-27	2004-01-15	Takeda Chemical Industries Ltd	1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
EP1205478A4 (fr)	1999-08-06	2004-06-30	Takeda Chemical Industries Ltd	INHIBITEURS DE p38MAP KINASE
AU4722801A (en)	2000-02-24	2001-09-03	Xenon Genetics Inc	Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
WO2001074811A2 (fr)	2000-03-30	2001-10-11	Takeda Chemical Industries, Ltd.	Composes de 1,3-thiazole substitues, production et utilisation desdits composes
JP2002302488A (ja) *	2000-03-30	2002-10-18	Takeda Chem Ind Ltd	置換１，３−チアゾール化合物、その製造法および用途
WO2002051442A1 (fr)	2000-12-26	2002-07-04	Takeda Chemical Industries, Ltd.	Co-prescriptions
EP2272813B1 (fr) *	2001-04-24	2016-11-16	Massachusetts Institute of Technology (MIT)	Formation de liaisons carbone-oxygène catalysée au cuivre
US20050080113A1 (en)	2001-06-11	2005-04-14	Shigenori Ohkawa	Medicinal compositions
US6706739B2 (en) *	2001-08-21	2004-03-16	National Health Research Institute	Imidazolidinone compounds
AU2003256755A1 (en) *	2002-07-24	2004-02-09	Ptc Therapeutics, Inc.	Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
SE0301232D0 (sv) *	2003-04-25	2003-04-25	Astrazeneca Ab	Novel use
WO2005077937A1 (fr)	2004-01-09	2005-08-25	Cadila Healthcare Limited	Derives d'acide hydroxamique substitues utilises comme inhibiteurs de tnf
EP1621539A1 (fr)	2004-07-27	2006-02-01	Aventis Pharma S.A.	Dérivées d'urée cyclique substitués par un heterocycle, leur prépration et leur utilisation pharmaceutique comee inhibiteurs de kinases
BRPI0515505A (pt)	2004-09-20	2008-07-29	Xenon Pharmaceuticals Inc	derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
BRPI0712902A2 (pt) *	2006-06-05	2018-10-30	Novartis Ag	compostos orgânicos
KR20140019873A (ko) *	2006-08-15	2014-02-17	노파르티스 아게	증가된 지질 수준과 관련된 질환의 치료에 적합한 헤테로시클릭 화합물
MX2009002019A (es)	2006-08-24	2009-03-09	Novartis Ag	Derivados de 2-(pirazin-2-il)-tiazol y 2-(1h-pirazol-3-il)-tiazol asi como compuestos relacionados como inhibidores de la estearoil-coa-desaturasa (scd) para el tratamiento de trastornos metabolicos, cardiovasculares, y otros.
CA2662574A1 (fr) *	2006-09-22	2008-03-27	Novartis Ag	Composes organiques
AU2007336238A1 (en) *	2006-12-20	2008-06-26	Novartis Ag	2-substituted 5-membered heterocycles as SCD inhibitors
JP5507474B2 (ja) *	2008-02-20	2014-05-28	ノバルティスアーゲー	ステアロイル−ＣｏＡデサチュラーゼのヘテロ環式阻害剤
BRPI0913966A2 (pt)	2008-06-27	2015-11-17	Novartis Ag	compostos orgânicos

2007
- 2007-08-13 KR KR1020147001838A patent/KR20140019873A/ko not_active Withdrawn
- 2007-08-13 MX MX2009001634A patent/MX2009001634A/es active IP Right Grant
- 2007-08-13 NZ NZ574222A patent/NZ574222A/en not_active IP Right Cessation
- 2007-08-13 PE PE2011000441A patent/PE20110371A1/es not_active Application Discontinuation
- 2007-08-13 CA CA2660201A patent/CA2660201C/fr not_active Expired - Fee Related
- 2007-08-13 BR BRPI0716407-6A patent/BRPI0716407A2/pt not_active IP Right Cessation
- 2007-08-13 WO PCT/US2007/075802 patent/WO2008127349A2/fr not_active Ceased
- 2007-08-13 KR KR1020097005250A patent/KR20090040385A/ko not_active Ceased
- 2007-08-13 AR ARP070103586A patent/AR062360A1/es unknown
- 2007-08-13 NZ NZ598548A patent/NZ598548A/xx not_active IP Right Cessation
- 2007-08-13 CN CN2007800303661A patent/CN101535303B/zh not_active Expired - Fee Related
- 2007-08-13 ES ES07873509.9T patent/ES2597453T3/es active Active
- 2007-08-13 PE PE2011000443A patent/PE20110341A1/es not_active Application Discontinuation
- 2007-08-13 PE PE2007001082A patent/PE20081316A1/es not_active Application Discontinuation
- 2007-08-13 UA UAA200900859A patent/UA96766C2/ru unknown
- 2007-08-13 US US12/377,499 patent/US8063084B2/en not_active Expired - Fee Related
- 2007-08-13 RU RU2009109147/04A patent/RU2009109147A/ru unknown
- 2007-08-13 EP EP07873509.9A patent/EP2054408B1/fr active Active
- 2007-08-13 MY MYPI20090434A patent/MY153263A/en unknown
- 2007-08-13 JP JP2009524754A patent/JP4972690B2/ja not_active Expired - Fee Related
- 2007-08-13 KR KR1020117011700A patent/KR20110077006A/ko not_active Ceased
- 2007-08-13 TW TW096129875A patent/TWI404718B/zh not_active IP Right Cessation
- 2007-08-13 AU AU2007351498A patent/AU2007351498B2/en not_active Ceased
- 2007-08-13 KR KR1020127026540A patent/KR20130036080A/ko not_active Ceased
- 2007-08-13 CL CL200702348A patent/CL2007002348A1/es unknown
2009
- 2009-01-13 ZA ZA2009/00263A patent/ZA200900263B/en unknown
- 2009-01-15 IL IL196562A patent/IL196562A0/en unknown
- 2009-01-16 CR CR10566A patent/CR10566A/es not_active Application Discontinuation
- 2009-02-06 GT GT200900027A patent/GT200900027A/es unknown
- 2009-02-13 TN TN2009000045A patent/TN2009000045A1/fr unknown
- 2009-02-13 CO CO09014467A patent/CO6241156A2/es active IP Right Grant
- 2009-02-20 MA MA31653A patent/MA30655B1/fr unknown
- 2009-03-11 NO NO20091083A patent/NO20091083L/no not_active Application Discontinuation
2011
- 2011-09-13 US US13/231,075 patent/US8293768B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2010501488A (ja)	2010-01-21
IL196562A0 (en)	2009-11-18
CA2660201C (fr)	2016-05-03
MX2009001634A (es)	2009-02-25
BRPI0716407A2 (pt)	2014-05-20
US8293768B2 (en)	2012-10-23
AR062360A1 (es)	2008-11-05
EP2054408B1 (fr)	2016-07-13
US20120004164A1 (en)	2012-01-05
NZ598548A (en)	2013-09-27
RU2009109147A (ru)	2010-09-27
US8063084B2 (en)	2011-11-22
CN101535303A (zh)	2009-09-16
CN101535303B (zh)	2012-07-18
PE20110341A1 (es)	2011-06-21
UA96766C2 (ru)	2011-12-12
WO2008127349A2 (fr)	2008-10-23
CO6241156A2 (es)	2011-01-20
NZ574222A (en)	2012-03-30
PE20081316A1 (es)	2008-10-16
MY153263A (en)	2015-01-29
NO20091083L (no)	2009-04-28
CL2007002348A1 (es)	2008-08-08
KR20110077006A (ko)	2011-07-06
EP2054408A2 (fr)	2009-05-06
KR20090040385A (ko)	2009-04-23
TWI404718B (zh)	2013-08-11
US20100233116A1 (en)	2010-09-16
GT200900027A (es)	2010-06-01
AU2007351498A1 (en)	2008-10-23
KR20130036080A (ko)	2013-04-09
CR10566A (es)	2009-03-11
WO2008127349A3 (fr)	2009-02-12
KR20140019873A (ko)	2014-02-17
MA30655B1 (fr)	2009-08-03
PE20110371A1 (es)	2011-06-24
CA2660201A1 (fr)	2008-10-23
ZA200900263B (en)	2011-11-30
JP4972690B2 (ja)	2012-07-11
ES2597453T3 (es)	2017-01-18
AU2007351498B2 (en)	2012-04-05
TW200815427A (en)	2008-04-01

Publication	Publication Date	Title
TN2009000045A1 (en)	2010-08-19	Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level
WO2007143597A3 (fr)	2008-04-10	Composés organiques
JO3014B1 (ar)	2016-09-05	مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة
WO2009156484A3 (fr)	2010-05-14	Composés organiques
MX2009006728A (es)	2009-09-09	Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
MX2009006704A (es)	2009-06-30	Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
TN2010000203A1 (en)	2011-11-11	Beta-lactamase inhibitors
MX2009003658A (es)	2009-04-22	Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
MX2009004059A (es)	2009-04-27	Triazoles biciclicos como moduladores de proteina cinasa.
SG161318A1 (en)	2010-05-27	Heterocyclic inhibitors of mek and methods of use thereof
EA200901308A1 (ru)	2010-04-30	Ингибиторы белка, активирующего 5-липоксигеназу (flap)
MX2009010894A (es)	2009-10-26	Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa.
PL1979355T3 (pl)	2011-04-29	Pochodne spiro imidazoli jako modulatory PPAR
EP2476679A3 (fr)	2012-10-31	Triazoles substitués utilisés comme inhibiteurs AXL
WO2007092751A3 (fr)	2007-12-27	Composés et procédés pour moduler fxr
MX2009006339A (es)	2009-08-21	Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
MX2009007337A (es)	2009-07-15	Indazoles sustituidos con 5-piridinona.
WO2007130780A3 (fr)	2008-02-14	Modulateurs des récepteurs vr1 dérivés du benzimidazole
EA201000895A1 (ru)	2010-12-30	Композиции и способы для лечения лизосомных болезней
TW200630090A (en)	2006-09-01	Triazoles useful as inhibitors of protein kinases
TN2012000085A1 (en)	2013-09-19	Pyrazole derivatives which modulate stearoyl-coa desaturase
TW200806293A (en)	2008-02-01	Methods of treatment with CETP inhibitors
WO2007081808A3 (fr)	2008-04-03	Composes et derives pour le traitement d’etats medicaux par modulation de l’activite de la lipase hormono-sensible
TN2010000378A1 (en)	2011-12-29	Heterocyclic inhibitors of stearoyl-coa desaturase
TN2010000598A1 (en)	2012-05-24	Organic compounds